Contraindicated in patients who have had a severe systemic reaction during prior administration of any equine gamma globulin preparation.
- Trade Name: Atgam (Pfizer)
- Indications: Management of allograft rejection in renal transplant patients, prophylaxis of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation
- Class: Immunosuppressant
- Half-life: 3–9 days
- Clinically important, potentially hazardous interactions with:
None known
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
